[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Medical News and Perspectives
September 17, 2003

Scientists Probe Cancer Cell Resistance

JAMA. 2003;290(11):1435-1437. doi:10.1001/jama.290.11.1435

Washington DC—Heralded as therapeutic smart bombs that zero in on cancer cells and leave healthy cells intact, targeted cancer therapies appear to offer a safer, more effective approach to fighting cancer than conventional chemotherapy. Drugs such as imatinib mesylate (Gleevec), one of the most successful examples of these new targeted therapies to date, are designed to interfere with the aberrant molecular mechanisms that promote the abnormal growth of cells.

First Page Preview View Large
First page PDF preview
First page PDF preview
×